Alkermes plc (NASDAQ: ALKS) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 107.67 | EPS (ttm) | 0.40 | Insider Own | 1.89% | Shs Outstand | 167.76M | Perf Week | -5.61% |
| Market Cap | 7.28B | Forward P/E | 63.70 | EPS next Y | 0.68 | Insider Trans | -4.30% | Shs Float | 155.14M | Perf Month | -13.53% |
| Enterprise Value | 8.34B | PEG | - | EPS next Q | -0.08 | Inst Own | 107.00% | Short Float | 9.49% | Perf Quarter | -3.56% |
| Income | 66.24M | P/S | 4.37 | EPS this Y | -225.91% | Inst Trans | 0.00% | Short Ratio | 7.51 | Perf Half Y | 52.78% |
| Sales | 1.67B | P/B | 4.00 | EPS next Y | 242.36% | ROA | 1.51% | Short Interest | 14.72M | Perf YTD | 55.08% |
| Book/sh | - | P/C | 28.78 | EPS next 5Y | - | ROE | 3.72% | 52W High | 55.67 -22.06% | Perf Year | 55.69% |
| Cash/sh | - | P/FCF | 32.84 | EPS past 3/5Y | - | ROIC | 2.12% | 52W Low | 26.99 60.76% | Perf 3Y | 45.56% |
| Dividend Est. | - | EV/EBITDA | 38.25 | Sales past 3/5Y | 9.90% 7.27% | Gross Margin | 84.56% | Volatility | 3.53% 2.92% | Perf 5Y | 42.17% |
| Dividend TTM | - | EV/Sales | 5.00 | EPS Y/Y TTM | -82.49% | Oper. Margin | 7.03% | ATR (14) | 1.56 | Perf 10Y | -8.50% |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | Sales Y/Y TTM | 7.06% | Profit Margin | 3.96% | RSI (14) | 29.82 | Recom | 2.55 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.30 | EPS Q/Q | 34.62% | SMA20 | -7.46% | Beta | 0.26 | Target Price | 60.60 |
| Payout | 0.00% | Debt/Eq | 0.87 | Sales Q/Q | 26.85% | SMA50 | -11.62% | Rel Volume | 3.58 | Prev Close | 46.71 |
| Employees | 2,050 | LT Debt/Eq | 0.03 | Earnings | Oct 28 | SMA200 | 12.80% | Avg Volume | 1.88M | Price | 43.39 |
| IPO Date | Jul 16, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2649.81% 8.45% | Net Debt/EBITDA | 4.87 | Volume | 6,741,686 | Change | -7.11% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Reiterated | Piper Sandler | Overweight | $45 → $65 |
| Jul-20-26 | Reiterated | Stifel Nicolaus | $36 → $63 | |
| Jul-02-26 | Reiterated | Mizuho | Outperform | $45 → $65 |
| Jun-29-26 | Downgrade | B of A Securities | Neutral → Underperform | |
| Jun-18-26 | Reiterated | Needham | Buy | $50 → $54 |
| Jun-09-26 | Reiterated | RBC Capital | Outperform | $47 → $56 |
| May-06-26 | Reiterated | Needham | Buy | $43 → $50 |
| Feb-26-26 | Reiterated | H.C. Wainwright | Neutral | $46 → $43 |
| Feb-23-26 | Initiated | Wolfe Research | Outperform | $45 |
| Oct-28-25 | Reiterated | Jefferies | Buy | $50 → $56 |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,668 | 1,476 | 1,558 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 258 | 196 | 245 | — | — | — | — | — | — | |
| Gross Profit | 1,410 | 1,279 | 1,312 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 845 | 715 | 645 | — | — | — | — | — | — | |
| Research and Development | 391 | 324 | 245 | — | — | — | — | — | — | |
| Other Operating Expense | 58 | -14 | 2 | — | — | — | — | — | — | |
| Operating Income | 117 | 254 | 421 | — | — | — | — | — | — | |
| Interest Expense | 59 | 12 | 23 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 40 | 50 | 46 | — | — | — | — | — | — | |
| Net Income Before Taxes | 97 | 291 | 444 | — | — | — | — | — | — | |
| Income Taxes | 32 | 50 | 72 | — | — | — | — | — | — | |
| Consolidated Net Income | 67 | 242 | 367 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 67 | 242 | 372 | — | — | — | — | — | — | |
| Net Income | 67 | 242 | 367 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.40 | 1.47 | 2.22 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.40 | 1.47 | 2.22 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.38 | 1.43 | 2.17 | — | — | — | — | — | — | |
| EBITDA | 218 | 331 | 495 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 114.18 | 19.57 | 13.25 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.34 | 3.13 | 3.05 | — | — | — | — | — | — | |
| Gross Margin | 84.53 | 86.65 | 84.21 | — | — | — | — | — | — | |
| Operating Margin | 7.01 | 17.21 | 27.02 | — | — | — | — | — | — | |
| Net Margin | 4.02 | 16.40 | 23.56 | — | — | — | — | — | — | |
| Shares Outstanding | 167 | 165 | 165 | — | — | — | — | — | — | |
| Market Capitalization | 7,246 | 4,617 | 4,745 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sep 03 '26 | Sale | 48.01 | 2,034 | 97,652 | 223,422 | Sep 03 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sep 01 '26 | Sale | 46.99 | 9,000 | 422,874 | 65,389 | Sep 01 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sep 01 '26 | Option Exercise | 24.59 | 5,000 | 122,950 | 74,389 | Sep 01 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Aug 17 '26 | Sale | 49.23 | 7,576 | 372,936 | 102,193 | Aug 17 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Aug 03 '26 | Sale | 48.58 | 9,000 | 437,220 | 69,389 | Aug 03 |
| snyderman nancy lynn MD | Director | Aug 03 '26 | Option Exercise | 46.72 | 44,472 | 2,077,732 | 59,867 | Aug 03 |
| snyderman nancy lynn MD | Director | Aug 03 '26 | Sale | 50.35 | 44,472 | 2,239,076 | 15,395 | Aug 03 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Aug 03 '26 | Option Exercise | 24.48 | 5,000 | 122,404 | 78,389 | Aug 03 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Aug 03 '26 | Sale | 48.58 | 2,034 | 98,812 | 225,456 | Aug 03 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Jul 06 '26 | Sale | 54.03 | 2,034 | 109,897 | 227,490 | Jul 06 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jul 01 '26 | Option Exercise | 19.34 | 5,000 | 96,700 | 82,389 | Jul 01 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jul 01 '26 | Sale | 51.51 | 9,000 | 463,621 | 73,389 | Jul 01 |
| Wright Christopher I | Director | Jun 12 '26 | Sale | 45.10 | 2,000 | 90,200 | 25,680 | Jun 12 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Jun 04 '26 | Sale | 43.05 | 2,034 | 87,564 | 229,524 | Jun 04 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jun 01 '26 | Option Exercise | 19.34 | 5,000 | 96,700 | 86,389 | Jun 01 |